Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7210457 | 0.97 | TLR7 (0.62) | TLR7 | |
| SCHEMBL2060185 | 0.94 | TLR7 (0.61) | TLR7 | |
| SCHEMBL510225 | 0.90 | TLR7 (0.74) | TLR7 | |
| SCHEMBL7207331 | 0.89 | TLR7 (0.70) | TLR7 | |
| SCHEMBL7205092 | 0.88 | TLR7 (0.66) | TLR7 | |
| SCHEMBL25511858 | 0.88 | TLR7 (0.55) | TLR7 | |
| SCHEMBL43700 | 0.87 | TLR7 (0.74) | TLR7 | |
| SCHEMBL29386203 | 0.87 | TLR7 (0.74) | TLR7 | |
| SCHEMBL7206493 | 0.87 | TLR7 (0.62) | TLR7 | |
| SCHEMBL7209998 | 0.87 | TLR7 (0.61) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928500-A2 | MODULATION OF TLR-MEDIATED IMMUNE RESPONSES USING ADAPTOR OLIGONUCLEOTIDES | Coley Pharmaceutical GmbH (DE) | 2008-06-11 | — | — | EP | claimed |
| WO-2007038720-A2 | MODULATION OF TLR-MEDIATED IMMUNE RESPONSES USING ADAPTOR OLIGONUCLEOTIDES | COLEY PHARMACEUTICAL GMBH (DE) | 2007-04-05 | — | — | WO | claimed |
| US-20250283096-A1 | SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOSTIMULATORY AGENTS FOR PROPHYLACTIC AND THERAPEUTIC USE | FLASHPOINT THERAPEUTICS, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-11957788-B2 | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications | EXICURE OPERATING COMPANY (US) | 2024-04-16 | — | — | US | disclosed |
| US-20220257512-A1 | MULTIVALENT DELIVERY OF IMMUNE MODULATORS BY LIPOSOMAL SPHERICAL NUCLEIC ACIDS FOR PROPHYLACTIC OR THERAPEUTIC APPLICATIONS | EXICURE OPERATING COMPANY (US) | 2022-08-18 | — | — | US | disclosed |
| US-11123294-B2 | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications | EXICURE OPERATING COMPANY (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210102211-A1 | SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOSTIMULATORY AGENTS FOR PROPHYLACTIC AND THERAPEUTIC USE | EXICURE, INC. (US) | 2021-04-08 | — | — | US | disclosed |
| US-10894963-B2 | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use | EXICURE, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10837018-B2 | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use | EXICURE, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| CN-106535876-B | Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications | 埃克西奎雷股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20200069587-A1 | MULTIVALENT DELIVERY OF IMMUNE MODULATORS BY LIPOSOMAL SPHERICAL NUCLEIC ACIDS FOR PROPHYLACTIC OR THERAPEUTIC APPLICATIONS | EXICURE, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| EP-1928500-A2 | MODULATION OF TLR-MEDIATED IMMUNE RESPONSES USING ADAPTOR OLIGONUCLEOTIDES | Coley Pharmaceutical GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008039538-A2 | COMPOSITIONS OF TLR LIGANDS AND ANTIVIRALS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070287664-A1 | Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto | SCHERING CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287664-A1 | Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto | SCHERING CORPORATION | 2007-12-13 | — | — | US | disclosed |
| WO-2007111866-A2 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007038720-A2 | MODULATION OF TLR-MEDIATED IMMUNE RESPONSES USING ADAPTOR OLIGONUCLEOTIDES | COLEY PHARMACEUTICAL GMBH (DE) | 2007-04-05 | — | — | WO | disclosed |
| EP-1035123-B1 | NOVEL HETEROCYCLIC COMPOUNDS | SUMITOMO PHARMA (JP) | 2003-08-20 | — | — | EP | disclosed |
| US-6329381-B1 | INTERFERONS, VIRICIDES AND ANTICARCINOGENIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1035123-A1 | NOVEL HETEROCYCLIC COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287664-A1 | Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto | CYP3A43, CYP3A4, CYP3A7 | TLR7 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.